Jefferson Life Sciences portfolio
The short answer
Jefferson Life Sciences has been named as an investor in 1 reported round worth about $297M in disclosed capital, backing Oxford spin-out OMass Therapeutics. Most recent: Oxford spin-out OMass Therapeutics (€275 million, 2026-10-16).
- Deals logged
- 1
- Companies
- 1
- Disclosed rounds
- $297M
- Top sector
- Health
Every deal on record
| Date | Company | Amount | Round | Source |
|---|---|---|---|---|
| 2026-10-16 | Oxford spin-out OMass Therapeutics | €275 million | Series C | EU-Startups |
How this is measured
Deals come from public funding announcements, credited in the source column. Only investors named in reports are listed; nothing is estimated.